Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
Kallieri M, Papaioannou AI, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E, Makris M, Ntakoula M, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S.
Kallieri M, et al. Among authors: tzanakis n.
Clin Exp Allergy. 2024 Apr;54(4):286-290. doi: 10.1111/cea.14436. Epub 2023 Dec 12.
Clin Exp Allergy. 2024.
PMID: 38084474
No abstract available.